Qualitative and quantitative variables that affect the potency of Fc-mediated effector function in vitro and in vivo: Considerations for passive immunization using non-neutralizing antibodies

Current HIV Research

Volumn 11, Issue 5, 2013, Pages 354-364

  Lewis, George K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody structure; Antibody dependent cell mediated cytotoxicity; Antigen structure; Fc mediated effector function

Indexed keywords

B LYMPHOCYTE ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO;

ACTIVE IMMUNIZATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CROSS LINKING; CYTOTOXICITY; DISEASE COURSE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTAGENESIS; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); VIREMIA; VIRUS INHIBITION;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FC FRAGMENTS; RECEPTORS, IGG;

EID: 84889056040     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X113116660060     Document Type: Article

References (115)

1. Rook AH, Lane HC, Folks T, et al. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol 1987; 138: 1064-7.
2. Ljunggren K, Bottiger B, Biberfeld G, et al. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol 1987; 139: 2263-7.
3. Goudsmit J, Ljunggren K, Smit L, Jondal M, Fenyo EM. Biological significance of the antibody response to HIV antigens expressed on the cell surface. Arch Virol 1988; 103: 189-206.
4. Ljunggren K, Moschese V, Broliden PA, et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990; 161: 198-202.
5. Ojo-Amaize E, Nishanian PG, Heitjan DF, et al. Serum and effectorcell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression. J Clin Immunol 1989; 9: 454-61.
6. Sawyer LA, Katzenstein DA, Hendry RM, et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990; 6: 341-56.
7. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibodydependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157: 2168-73.
8. Dalgleish A, Sinclair A, Steel M, et al. Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin Exp Immunol 1990; 81: 5-10.
9. Jenkins M, Landers D, Williams-Herman D, et al. Association between anti-human immunodeficiency virus type 1 (HIV-1) antibodydependent cellular cytotoxicity antibody titers at birth and vertical transmission of HIV-1. J Infect Dis 1994; 170: 308-12.
10. Broliden K, Sievers E, Tovo PA, et al. Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children. Clin Exp Immunol 1993; 93: 56-64.
11. Ahmad A, Morisset R, Thomas R, Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIVinfected individuals. J Acquir Immune Defic Syndr 1994; 7: 428-37.
12. Tranchat C, Van de Perre P, Simonon-Sorel A, et al. Maternal humoral factors associated with perinatal human immunodeficiency virus type-1 transmission in a cohort from Kigali, Rwanda, 1988-1994. J Infect 1999; 39: 213-20.
13. Forthal DN, Landucci G, Keenan B. Relationship between antibodydependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses 2001; 17: 553-61.
14. Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001; 21: 227-33.
15. Nag P, Kim J, Sapiega V, et al. Women with cervicovaginal antibodydependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 2004; 190: 1970-8.
16. Chung AW, Isitman G, Navis M, et al. Immune escape from HIVspecific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 2011; 108: 7505-10.
17. Chung AW, Navis M, Isitman G, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 2011; 58: 127-31.
18. Dugast AS, Tonelli A, Berger CT, et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 2011; 415: 160-7.
19. Liu Q, Sun Y, Rihn S, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009; 83: 8705-12.
20. Jia M, Li D, He X, et al. Impaired natural killer cell-induced antibodydependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression. Clin Exp Immunol 2013; 171: 107-16.
21. Forthal DN, Landucci G, Bream J, et al. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 2007; 179: 7916-23.
22. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002; 18: 1197-205.
23. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001; 75: 6953-61.
24. Sun Y, Asmal M, Lane S, et al. Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys. J Virol 2011; 85(14): 6906-12.
25. Asmal M, Sun Y, Lane S, et al. Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses. J Virol 2011; 85: 5465-75.
26. He X, Li D, Luo Z, et al. Compromised NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Chronic SIV/SHIV Infection. PloS One 2013; 8: e56309.
27. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174: 2185-9.
28. Ohkawa S, Wilson LA, Larosa G, et al. Immune responses induced by prototype vaccines for AIDS in rhesus monkeys. AIDS Res Hum Retroviruses 1994; 10: 27-38.
29. von Gegerfelt A, Nilsson C, Putkonen P, Broliden K. Broadly reactive HIV-2 and SIVmac specific antibody-dependent cellular cytotoxicity in immunized and infected cynomolgus monkeys. Vaccine 1994; 12: 1203-8.
30. Putkonen P, Nilsson C, Walther L, et al. Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys. J Med Primatol 1994; 23: 89-94.
31. Patterson LJ, Beal J, Demberg T, et al. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89. 6P challenge in Mamu-A*01 negative rhesus macaques. Virology 2008; 374: 322-37.
32. Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with tat/env compared with multigenic vaccines. J Immunol 2009; 182: 3718-27.
33. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89. 6P challenge in rhesus macaques. J Virol 2010; 84: 7161-73.
34. Xiao P, Patterson LJ, Kuate S, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated lowdose rectal SIV(mac251) challenge. J Virol 2012; 86: 4644-57.
35. Brocca-Cofano E, McKinnon K, Demberg T, et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011; 29: 3310-9.
36. Alpert MD, Harvey JD, Lauer WA, et al. ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIV(mac)251 Challenge. PLoS Pathog 2012; 8: e1002890.
37. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate. J Immunol 2007; 178: 6596-603.
38. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366: 1275-86.
39. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191: 654-65.
40. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.
41. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVACHIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12: 531-7.
42. Ferrari G, Pollara J, Kozink D, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85: 7029-36.
43. Guan Y, Pazgier M, Sajadi MM, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci USA 2013; 110: E69-78.
44. Bonsignori M, Pollara J, Moody MA, et al. ADCC-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. J Virol 2012; 86(21): 11521-32.
45. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 2013; 110(22): 9019-24.
46. Florese RH, Van Rompay KK, Aldrich K, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicitymediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177: 4028-36.
47. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449: 101-4.
48. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15(8): 951-4.
49. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012; 86: 6189-96.
50. Prince AM, Reesink H, Pascual D, et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991; 7: 971-3.
51. Putkonen P, Thorstensson R, Ghavamzadeh L, et al. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 1991; 352: 436-8.
52. Safrit JT, Fung MS, Andrews CA, et al. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 1993; 7: 15-21.
53. Gauduin MC, Safrit JT, Weir R, Fung MS, Koup RA. Pre-and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J Infect Dis 1995; 171: 1203-9.
54. Parren PW, Ditzel HJ, Gulizia RJ, et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995; 9: F1-6.
55. Gauduin M-C, parren PWHI, Weir R, et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3: 1389-93.
56. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-10.
57. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75: 8340-7.
58. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol 2001; 8: 350-8.
59. Ferrantelli F, Rasmussen RA, Buckley KA, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189: 2167-73.
60. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108(27): 11181-6.
61. Moldt B, Rakasz EG, Schultz N, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012; 109: 18921-5.
62. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2013.
63. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: 1024-27.
64. Pantophlet R, Ollmann Saphire E, Poignard P, et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003; 77: 642-58.
65. Cavacini LA, Emes CL, Wisnewski AV, et al. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 1998; 14: 1271-80.
66. Moldt B, Schultz N, Dunlop DC, et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J Virol 2011; 85: 10572-81.
67. Zhang L, Ribeiro RM, Mascola JR, et al. Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J Virol 2004; 78: 5520-2.
68. Arthur LO, Bess JW, Jr., Chertova EN, et al. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses 1998; 14 Suppl 3: S311-9.
69. Rossio JL, Esser MT, Suryanarayana K, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998; 72: 7992-8001.
70. O'Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000; 74: 10074-80.
71. Robinson WE, Jr., Gorny MK, Xu JY, Mitchell WM, Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 1991; 65: 4169-76.
72. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991; 65: 4832-8.
73. Buchacher A, Predl R, Strutzenberger W, et al. Electrofusion and EBVtransformation for PBL-immortalization: generation of human monoclonal antibodies against HIV-1 proteins. AIDS Res Hum Retroviruses 1994; 10: 359-69.
74. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80: 6177-81.
75. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5: e1000433.
76. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84: 1302-13.
77. van Gils MJ, Sanders RW. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013; 435: 46-56.
78. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 2012; 12: 13.
79. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann NY Acad Sci 2012; 1253: 170-80.
80. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature reviews. Immunology 2004; 4: 89-99.
81. Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 2009; 157: 244-54.
82. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10: 328-43.
83. Tyler DS, Nastala CL, Stanley SD, et al. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J Immunol 1989; 142: 1177-82.
84. Tyler DS, Stanley SD, Zolla-Pazner S, et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990; 145: 3276-82.
85. Koup RA, Robinson JE, Nguyen QV, et al. Antibody-dependent cellmediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS 1991; 5: 1309-14.
86. Moore JP, Cao Y, Conley AJ, et al. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. J Acquir Immune Defic Syndr 1994; 7: 332-9.
87. Bialuk I, Whitney S, Andresen V, et al. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 2011; 30: 78-94.
88. Pancera M, Majeed S, Ban YE, et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010; 107: 1166-71.
89. Sen J, Yan T, Wang J, et al. Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. Biochemistry 2010; 49: 5057-65.
90. Moore PL, Crooks ET, Porter L, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006; 80: 2515-28.
91. Goldstein B, Faeder JR, Hlavacek WS. Mathematical and computational models of immune-receptor signalling. Nat Rev Immunol 2004; 4: 445-56.
92. Holowka D, Sil D, Torigoe C, Baird B. Insights into immunoglobulin E receptor signaling from structurally defined ligands. Immunol Rev 2007; 217: 269-79.
93. Wiegel FW, Perelson AS. Configurations of a polymeric antigen adsorbed to a B-cell membrane. J Theor Biol 1981; 88: 533-68.
94. Gomez-Roman VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 2006; 308: 53-67.
95. Pollara J, Hart L, Brewer F, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011; 79: 603-12.
96. Wu H, Kwong PD, Hendrickson WA. Dimeric association and segmental variability in the structure of human CD4. Nature 1997; 387: 527-30.
97. Moldovan MC, Yachou A, Levesque K, et al. CD4 dimers constitute the functional component required for T cell activation. J Immunol 2002; 169: 6261-8.
98. Matthias LJ, Azimi I, Tabrett CA, Hogg PJ. Reduced monomeric CD4 is the preferred receptor for HIV. J Biol Chem 2010; 285: 40793-9.
99. Berzofsky JA, Berkower IJ. Antigen-antibody interactions and monoclonal antibodies. In: W E Paul, Ed. Fundamental Immunology. New York: Lipincott Williams & Wilkins 2013; 183-214.
100. Harms BD, Kearns JD, Su SV, et al. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Methods Enzymol 2012; 502: 67-87.
101. Crothers DM, Metzger H. The influence of polyvalency on the binding properties of antibodies. Immunochemistry 1972; 9: 341-57.
102. DeLisi C, Perelson A. The kinetics of aggregation phenomena. I. Minimal models for patch formation of lymphocyte membranes. J Theor Biol 1976; 62: 159-210.
103. Posner RG, Wofsy C, Goldstein B. The kinetics of bivalent ligandbivalent receptor aggregation: ring formation and the breakdown of the equivalent site approximation. Math Biosci 1995; 126: 171-90.
104. Dembo M, Goldstein B, Sobotka AK, Lichtenstein LM. Histamine release due to bivalent penicilloyl haptens: control by the basophil plasma membrane. J Immunol 1978; 121: 354-8.
105. Goodner K, Horsfall FL. The Protective Action of Type I Antipneumococcus Serum in Mice: I. The Quantitative Aspects of the Mouse Protection Test. J Exp Med 1935; 62: 359-74.
106. Goodner K, Horsfall FL. The Protective Action of Type I Antipneumococcus Serum in Mice: Iv. The Prozone. J Exp Med 1936; 64: 369-75.
107. Perlmann P, Perlmann H. Contactual lysis of antibody-coated chicken erythrocytes by purified lymphocytes. Cell Immunol 1970; 1: 300-15.
108. Gray ES, Madiga MC, Moore PL, et al. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009; 83: 11265-74.
109. Gray ES, Taylor N, Wycuff D, et al. Antibody specificities associated with neutralization breadth in plasma from HIV-1 subtype C infected blood donors. J Virol 2009; 83(17): 8925-37.
110. Gray ES, Taylor N, Wycuff D, et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 2009; 83: 8925-37.
111. Taborda CP, Casadevall A. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozonelike effects in passive protection experiments. J Immunol 2001; 166: 2100-7.
112. Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol 2003; 170: 3621-30.
113. Hlavacek WS, Perelson AS, Sulzer B, et al. Quantifying aggregation of IgE-FcepsilonRI by multivalent antigen. Biophys J 1999; 76: 2421-31.
114. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-6.
115. Smalls-Mantey A, Doria-Rose N, Klein R, et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012; 86: 8672-80.